{"id":"https://openalex.org/W4416630753","doi":"https://doi.org/10.1016/j.jlb.2025.100370","title":"Tumor-Informed Circulating Tumor DNA (ctDNA) in Advanced NSCLC Treated with Pembrolizumab \u00b1 Chemotherapy","display_name":"Tumor-Informed Circulating Tumor DNA (ctDNA) in Advanced NSCLC Treated with Pembrolizumab \u00b1 Chemotherapy","publication_year":2025,"publication_date":"2025-11-01","ids":{"openalex":"https://openalex.org/W4416630753","doi":"https://doi.org/10.1016/j.jlb.2025.100370"},"language":"en","primary_location":{"id":"doi:10.1016/j.jlb.2025.100370","doi":"https://doi.org/10.1016/j.jlb.2025.100370","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jlb.2025.100370","pdf_url":"https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00086-4/pdf","source":{"id":"https://openalex.org/S4387291454","display_name":"The Journal of Liquid Biopsy","issn_l":"2950-1954","issn":["2950-1954"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Liquid Biopsy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00086-4/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039491281","display_name":"Diego Hern\u00e1n Enrico","orcid":"https://orcid.org/0000-0003-4121-6855","observed_orcids":["https://orcid.org/0000-0003-4121-6855"]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Diego Enrico","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5095694869","display_name":"Gisela Vargas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Gisela Vargas","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031546707","display_name":"Wulfson Gabriela","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Gabriela Wulfson","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004786877","display_name":"Florencia Tsou","orcid":"https://orcid.org/0000-0002-0322-0434","observed_orcids":["https://orcid.org/0000-0002-0322-0434"]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Florencia Tsou","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5095694870","display_name":"Delfina Peralta Tanco","orcid":"https://orcid.org/0009-0007-8608-5429","observed_orcids":["https://orcid.org/0009-0007-8608-5429"]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Delfina Peralta Tanco","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020571654","display_name":"Carmen Sof\u00eda Pupareli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Carmen Pupareli","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081067899","display_name":"Federico Waisberg","orcid":"https://orcid.org/0000-0003-4435-5068","observed_orcids":["https://orcid.org/0000-0003-4435-5068"]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Federico Waisberg","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Milena Revelli Ling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Milena Revelli Ling","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102942492","display_name":"Mat\u00edas F. Chac\u00f3n","orcid":"https://orcid.org/0000-0002-4935-9773","observed_orcids":["https://orcid.org/0000-0002-4935-9773"]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Mat\u00edas Chac\u00f3n","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044591512","display_name":"Claudio Mart\u00edn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125926","display_name":"Instituto Alexander Fleming","ror":"https://ror.org/02b0zvv74","country_code":"AR","type":"healthcare","lineage":["https://openalex.org/I4210125926"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Claudio Mart\u00edn","raw_affiliation_strings":["Instituto Alexander Fleming, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituto Alexander Fleming, Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210125926"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210125926"],"apc_list":{"value":2080,"currency":"USD","value_usd":2080},"apc_paid":{"value":2080,"currency":"USD","value_usd":2080},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"9","issue":null,"first_page":"100370","last_page":"100370"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4203999936580658,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4203999936580658,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.4074999988079071,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.1371999979019165,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.9959999918937683},{"id":"https://openalex.org/keywords/liquid-biopsy","display_name":"liquid biopsy","score":0.8429999947547913},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9160000085830688},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7590000033378601},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.6700000166893005},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.8360000252723694},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.9010000228881836},{"id":"https://openalex.org/keywords/first-line-immunotherapy","display_name":"first-line immunotherapy","score":0.7620000243186951}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8325999975204468},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7103999853134155},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6049000024795532},{"id":"https://openalex.org/C2781335228","wikidata":"https://www.wikidata.org/wiki/Q19596321","display_name":"Circulating tumor DNA","level":3,"score":0.48899999260902405},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4652000069618225},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.4034000039100647},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3522999882698059},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.33709999918937683},{"id":"https://openalex.org/C61238886","wikidata":"https://www.wikidata.org/wiki/Q5121689","display_name":"Circulating tumor cell","level":4,"score":0.3361999988555908},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3328000009059906},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3174999952316284},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.3050000071525574},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.29910001158714294},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.29670000076293945},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.2957000136375427},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2915000021457672},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.2646999955177307},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2574000060558319}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jlb.2025.100370","doi":"https://doi.org/10.1016/j.jlb.2025.100370","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jlb.2025.100370","pdf_url":"https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00086-4/pdf","source":{"id":"https://openalex.org/S4387291454","display_name":"The Journal of Liquid Biopsy","issn_l":"2950-1954","issn":["2950-1954"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Liquid Biopsy","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jlb.2025.100370","doi":"https://doi.org/10.1016/j.jlb.2025.100370","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jlb.2025.100370","pdf_url":"https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00086-4/pdf","source":{"id":"https://openalex.org/S4387291454","display_name":"The Journal of Liquid Biopsy","issn_l":"2950-1954","issn":["2950-1954"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Liquid Biopsy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4416630753.pdf","grobid_xml":"https://content.openalex.org/works/W4416630753.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3139130539","https://openalex.org/W3032542782","https://openalex.org/W7169848762","https://openalex.org/W4412439524","https://openalex.org/W4380870298","https://openalex.org/W4380870598","https://openalex.org/W4411709049","https://openalex.org/W2612093527","https://openalex.org/W2898157583","https://openalex.org/W4417333415"],"abstract_inverted_index":{"Introduction:":[0],"Currently":[1],"available":[2],"biomarkers":[3],"lack":[4],"precision":[5],"in":[6,42],"predicting":[7],"which":[8],"patients":[9],"with":[10],"advanced":[11],"non-small":[12],"cell":[13],"lung":[14],"cancer":[15],"(NSCLC)":[16],"will":[17],"benefit":[18],"from":[19],"first-line":[20],"immunotherapy":[21],"strategies.":[22],"An":[23],"early":[24,40],"pharmacodynamic":[25],"indicator":[26],"of":[27],"resistance":[28],"could":[29],"enable":[30],"timely":[31],"treatment":[32,54],"adaptation.":[33],"This":[34],"study":[35],"aimed":[36],"to":[37,57],"evaluate":[38],"whether":[39],"changes":[41],"circulating":[43],"tumor":[44],"DNA":[45],"(ctDNA)":[46],"after":[47],"initiating":[48],"pembrolizumab":[49],"\u00b1":[50],"chemotherapy":[51],"can":[52],"predict":[53],"response":[55],"prior":[56],"imaging.":[58]},"counts_by_year":[],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2025-11-25T00:00:00"}